MIMS Hosted

MIMS is pleased to announce a new section, MIMS Hosted , which provides healthcare professionals with access to relevant resources produced by external organisations.

If you would like to reach our audience of GPs, nurses and pharmacists by hosting your resource(s) in print, video or audio format on MIMS Hosted, please contact our team via our advertising and sponsorship page. Content must be compliant with MIMS editorial standards.


Resist the Resistance

Content supplied by Advanz Pharma

Manage lower UTIs with MacroBID®, a low-resistance, NICE-recommended treatment for lower UTIs. 1

MacroBID® is indicated for the treatment of and prophylaxis against acute or recurrent, uncomplicated lower UTIs or pyelitis either spontaneous or following surgical procedures, in patients over 12 years of age. 2

Download the MacroBID® leave piece

View MacroBID® prescribing information

References:

  1. NICE. Urinary tract infection (lower): antimicrobial prescribing (NG109). Published 31 October 2018.
  2. MacroBID® (nitrofurantoin 100 mg prolonged-release capsules) Summary of Product Characteristics. ADVANZ Pharma, 25 March 2019.

ADV/MAB/PM/0176; Date of preparation April 2020

Help eczema patients minimise the risk of infection

Content supplied by Alliance Pharmaceuticals Ltd

JB-000282; Date of preparation August 2020

App to help your patients 'Living with Eczema'

Content supplied by Alliance Pharmaceuticals Ltd

JB-000282; Date of preparation August 2020